CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 600,888	$ 537,702	$ 1,698,050	$ 1,580,021
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	42,095	31,400	98,760	92,582
Selling, general and administrative	207,255	178,706	607,061	522,667
Research and development	78,647	79,855	243,676	202,344
Intangible asset amortization	66,684	62,863	192,505	181,324
Acquired in-process research and development	10,000	51,775	215,250	109,975
Impairment charge	0	0	136,139	0
Total operating expenses	404,681	404,599	1,493,391	1,108,892
Income from operations	196,207	133,103	204,659	471,129
Interest expense, net	(27,428)	(17,861)	(72,134)	(54,017)
Foreign exchange loss	(639)	(1,033)	(2,235)	(3,577)
Income before income tax provision (benefit) and equity in loss of investees	168,140	114,209	130,290	413,535
Income tax provision (benefit)	19,283	10,903	22,750	(38,631)
Equity in loss of investees	623	1,030	2,338	2,791
Net income	$ 148,234	$ 102,276	$ 105,202	$ 449,375
Net income per ordinary share:
Basic (in dollars per share)	$ 2.67	$ 1.80	$ 1.89	$ 7.90
Diluted (in dollars per share)	$ 2.64	$ 1.78	$ 1.87	$ 7.80
Weighted-average ordinary shares used in per share calculations - basic (in shares)	55,545	56,674	55,637	56,860
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	56,236	57,438	56,297	57,647
Product sales, net
Revenues:
Total revenues	$ 596,949	$ 532,321	$ 1,685,357	$ 1,559,075
Royalties and contract revenues
Revenues:
Total revenues	$ 3,939	$ 5,381	$ 12,693	$ 20,946